2025-10-09 - Analysis Report
Okay, here's a report analyzing Eli Lilly and Co. (LLY), incorporating the provided data.

## Eli Lilly and Co. (LLY) Stock Analysis Report

**Ticker:** LLY
**Company Description:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

**Key Metrics:**

*   **LLY Cumulative Return:** 223.82%
*   **VOO Cumulative Return:** 99.62%
*   **Absolute Divergence (LLY - VOO):** 123.8%
*   **Divergence Range (Max: 248.5, Min: -33.6):**
*   **Relative Divergence:** 55.8%

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO). The absolute divergence of 123.8% indicates a substantial difference in cumulative returns. The relative divergence of 55.8% suggests that LLY's outperformance, while considerable, is positioned roughly in the middle range of its historical divergence from the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta | Cap(B) |
| :----------- | :------ | :------ | :----- | :--- | :----- |
| 2015-2017  | 11.0%   | 76.1%   | -17.0% | -0.0 | 75.7   |
| 2016-2018  | 39.0%   | 68.9%   | 24.0%  | -0.0 | 103.7  |
| 2017-2019  | 41.0%   | 68.9%   | 19.0%  | 0.4  | 117.8  |
| 2018-2020  | 34.0%   | 79.8%   | 10.0%  | 0.4  | 151.4  |
| 2019-2021  | 53.0%   | 79.8%   | 7.0%   | 0.5  | 247.6  |
| 2020-2022  | 64.0%   | 79.8%   | 65.0%  | 0.4  | 328.0  |
| 2021-2023  | 125.0%  | 78.9%   | 124.0% | 0.2  | 522.6  |
| 2022-2024  | 134.0%  | 81.2%   | 113.0% | 0.2  | 692.1  |
| 2023-2025  | 115.0%  | 83.5%   | 51.0%  | 0.2  | 758.1  |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate shows impressive growth, particularly in recent years (2021-2025).
*   **MDD:**  Maximum Drawdown is significant, indicating periods of substantial price decline.  Investors should be aware of this volatility.
*   **Alpha:**  Alpha is generally positive, especially in recent periods, suggesting LLY's performance is driven by factors beyond market movements.
*   **Beta:**  Beta is relatively low (often below 0.5), suggesting LLY is less sensitive to market fluctuations than the S&P 500.
*   **Cap(B):** The market capitalization has grown substantially over time, reflecting the company's increased value.

### 2. Recent Price Action

*   **Current Price:** 845.72
*   **Previous Close:** 843.63
*   **Change:** 0.25 (Slight increase)
*   **5-day Moving Average:** 838.82
*   **20-day Moving Average:** 774.46
*   **60-day Moving Average:** 746.92

**Analysis:**

LLY is trading above its 5, 20, and 60-day moving averages, indicating a short-term, medium-term, and long-term upward trend. The small recent price change suggests relatively stable trading in the very short term, but the fact that the price is above all the moving averages suggests a bullish trend overall.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 70.76 (Approaching overbought territory)
*   **PPO:** 1.32 (Positive, suggesting upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Delta_Previous_Relative_Divergence:** 14.6 (+) (Short-term increase in divergence)
*   **Expected Return:** 108.0% (Long-term, relative to S&P 500)

**Analysis:**

*   The **MRI** suggests that market conditions are favorable for investment in LLY.
*   The **RSI** approaching 70 suggests that the stock may be nearing overbought conditions, potentially indicating a pullback in the near term.
*   The positive **PPO** confirms upward momentum.
*   The **Hybrid Signal** recommends full investment based on the current indicators.
*   The positive **Delta_Previous_Relative_Divergence** indicates that LLY's outperformance relative to the S&P 500 has recently increased, reinforcing the bullish trend.
*   The very slight change in price (0.25) suggests that while there's an upward trend, recent price movement isn't drastic.
*   The **Expected Return** of 108.0% is extremely high, suggesting analysts anticipate significant outperformance compared to the S&P 500 over the long term.

### 4. Recent News & Significant Events

*   **Tariff turbulence deepens uncertainty across US supply chains** (FreightWaves): General economic concern.
*   **Sector Update: Health Care Stocks Advance Late Afternoon** (MT Newswires): Positive sector-specific news.
*   **Hims Stock, Up 138%: IBD Stock Of The Day Makes Another Breakout Run** (Investor's Business Daily): Not directly related to LLY, but indicates investor appetite for growth stocks in the healthcare space.
*   **Is Eli Lillyâ€™s Recent $1B India Investment a Game Changer for Its Valuation in 2025?** (Simply Wall St.): Positive strategic investment.
*   **Eli Lilly's Q3 Results Expected to Meet Estimates as Mounjaro Outperforms, Deutsche Bank Says** (MT Newswires): Positive expectations for upcoming earnings, driven by a specific product.

**Analysis:**

Recent news is generally positive. The $1B India investment signals growth potential.  The positive earnings expectations are crucial. The health care sector news is also a tailwind.

#### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.79)
*   **Target Price:** 887.19 (Average), 1190.00 (High), 650.00 (Low)
*   **Recent Rating Changes:**  No recent changes indicated

**Analysis:**

Analysts are generally bullish on LLY, with a consensus "Buy" rating and a target price significantly above the current price. The wide range in target prices (650.00 to 1190.00) suggests some uncertainty in the long-term outlook.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue   |
| :----------- | :--- | :-------- |
| 2025-08-07 | 6.30 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2025-08-07 | 3.29 | 11.30 B$ |

**Analysis:**

The most recent quarter (2025-08-07) shows a significant jump in both EPS and Revenue, suggesting strong growth.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-06-30 | $15.56B | 84.27%        |
| 2025-03-31 | $12.73B | 82.53%        |
| 2024-12-31 | $13.53B | 82.24%        |
| 2024-09-30 | $11.44B | 81.02%        |
| 2024-06-30 | $11.30B | 80.80%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
| :--------- | :-------- | :-------- |
| 2025-06-30 | $18.27B | 30.98%    |
| 2025-03-31 | $15.76B | 17.50%    |
| 2024-12-31 | $14.19B | 31.07%    |
| 2024-09-30 | $14.24B | 6.81%     |
| 2024-06-30 | $13.56B | 21.88%    |

**Analysis:**

*   **Revenue:**  Revenue has been consistently growing, with a significant increase in the most recent quarter.
*   **Profit Margin:** The profit margins are extremely high, indicating strong pricing power and efficient operations.
*   **Equity:** Equity has been increasing, reflecting the company's growing net worth.
*   **ROE:** Return on Equity is volatile but generally high, indicating efficient use of shareholder equity. The drop in 2024-09-30 requires further investigation.

### 7. Overall Summary

Eli Lilly and Co. (LLY) shows a strong bullish outlook based on the provided data:

*   **Outperformance:**  Significantly outperforming the S&P 500.
*   **Growth:**  Strong revenue and earnings growth, particularly in the most recent quarter.
*   **Profitability:**  Extremely high profit margins and ROE.
*   **Technicals:**  Positive technical indicators (MRI, PPO), although RSI is approaching overbought.
*   **Analyst Sentiment:**  Positive analyst ratings and price targets.
*   **News:**  Positive news related to strategic investments and earnings expectations.

**Considerations:**

*   **High Valuation:** The stock's high growth and profitability might already be priced in to some extent.
*   **RSI:** The approaching overbought RSI level suggests a possible near-term pullback.
*   **MDD:** The high Maximum Drawdown values indicate a potential for significant price swings, so investors should be aware of the risk.
*   **ROE volatility:** The drop in ROE for one quarter requires further investigation to understand the underlying cause.
*   **Tariff turbulence:** Be aware of macro economical uncertainly

**Overall Recommendation:**

Based on the data, LLY appears to be a strong investment with significant growth potential. However, investors should be aware of the potential for volatility and consider their risk tolerance. It may be wise to monitor the RSI and consider scaling into a position gradually, especially if the RSI enters overbought territory.
